472 related articles for article (PubMed ID: 16330205)
41. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract.
Hillcoat BL; Raghavan D; Matthews J; Kefford R; Yuen K; Woods R; Olver I; Bishop J; Pearson B; Coorey G
J Clin Oncol; 1989 Jun; 7(6):706-9. PubMed ID: 2654329
[TBL] [Abstract][Full Text] [Related]
42. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity.
Conti JA; Scher HI
Cancer; 1992 Dec; 70(11):2699-702. PubMed ID: 1384952
[TBL] [Abstract][Full Text] [Related]
43. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial.
Logothetis CJ; Finn LD; Smith T; Kilbourn RG; Ellerhorst JA; Zukiwski AA; Sella A; Tu SM; Amato RJ
J Clin Oncol; 1995 Sep; 13(9):2272-7. PubMed ID: 7666085
[TBL] [Abstract][Full Text] [Related]
44. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
Bajorin DF; McCaffrey JA; Hilton S; Mazumdar M; Kelly WK; Scher HI; Spicer J; Herr H; Higgins G
J Clin Oncol; 1998 Aug; 16(8):2722-7. PubMed ID: 9704723
[TBL] [Abstract][Full Text] [Related]
45. Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC.
Scher HI; Geller NL; Curley T; Tao Y
J Clin Oncol; 1993 Mar; 11(3):400-7. PubMed ID: 8445414
[TBL] [Abstract][Full Text] [Related]
46. [Clinical efficacy of modified M-VAC chemotherapy for advanced urothelial carcinoma and influence of squamous cell carcinoma-associated antigen on efficacy of the chemotherapy].
Otani N; Kumamoto Y; Tsukamoto T; Miyao N; Iwabe H; Yanase M; Takahashi A; Masumori N
Nihon Hinyokika Gakkai Zasshi; 1991 May; 82(5):786-91. PubMed ID: 1875572
[TBL] [Abstract][Full Text] [Related]
47. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
[TBL] [Abstract][Full Text] [Related]
48. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder.
Sternberg CN; Pansadoro V; Calabro F; Marini L; van Rijn A; Carli PD; Giannarelli D; Platania A; Rossetti A
Ann Oncol; 1999 Nov; 10(11):1301-5. PubMed ID: 10631456
[TBL] [Abstract][Full Text] [Related]
49. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
[TBL] [Abstract][Full Text] [Related]
50. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer.
Ueki O; Hisazumi H; Uchibayashi T; Naito K; Tajiri S; Takemae K; Kawaguchi K; Kameda K; Nishino A; Nango C
Cancer Chemother Pharmacol; 1992; 30 Suppl():S72-6. PubMed ID: 1394823
[TBL] [Abstract][Full Text] [Related]
51. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
[TBL] [Abstract][Full Text] [Related]
52. Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response.
Igawa M; Urakami S; Shiina H; Ishibe T; Kadena H; Usui T
Br J Urol; 1995 Sep; 76(3):321-4. PubMed ID: 7551840
[TBL] [Abstract][Full Text] [Related]
53. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
[TBL] [Abstract][Full Text] [Related]
54. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
55. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience.
Boutan-Laroze A; Mahjoubi M; Droz JP; Charrot P; Fargeot P; Kerbrat P; Caty A; Voisin PM; Spielmann M; Rey A
Eur J Cancer; 1991; 27(12):1690-4. PubMed ID: 1782084
[TBL] [Abstract][Full Text] [Related]
56. High dose chemotherapy for refractory urothelial carcinoma supported by peripheral blood stem cell transplantation.
Nishimura M; Nasu K; Ohta H; Shintaku M; Takahashi Y
Cancer; 1999 Nov; 86(9):1827-31. PubMed ID: 10547557
[TBL] [Abstract][Full Text] [Related]
57. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
Yamada Y; Itoh Y; Aoki S; Nakamura K; Taki T; Naruse K; Tobiume M; Zennami K; Katsuda R; Kato Y; Watanabe M; Nishikawa G; Minami M; Nakahira M; Ukai S; Sawada M; Kitamura A; Honda N
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1079-83. PubMed ID: 19277660
[TBL] [Abstract][Full Text] [Related]
58. M-VECA (methotrexate, vinblastine, epidoxorubicin and carboplatin) in the treatment of advanced urothelial carcinoma.
Lorusso V; Berardi F; Brandi M; Mastria A; Paradiso A; Catino AM; Tatulli C; De Lena M
Tumori; 1993 Jun; 79(3):191-4. PubMed ID: 8236502
[TBL] [Abstract][Full Text] [Related]
59. Factors affecting the outcome of patients with advanced urothelial cancer following chemotherapy with methotrexate, vinblastine, adriamycin, and cisplatin.
Igawa M; Ohkuchi T; Ueda M; Usui T
Cancer Chemother Pharmacol; 1992; 30 Suppl():S77-80. PubMed ID: 1394824
[TBL] [Abstract][Full Text] [Related]
60. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract.
Akaza H; Kotake T; Miyanaga N; Koiso K
Semin Oncol; 1994 Feb; 21(1 Suppl 1):70-4. PubMed ID: 7512280
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
